文献速递临床微生物临床免疫

基于免疫层析与产毒培养评估艰难梭菌感染风险因素

Evaluation of Risk Factors for Clostridium difficile Infection Based on Immunochromatography Testing and Toxigenic Culture Assay.
PubMed 文献 · J Clin Microbiol · 2018-11-27

研究对2012年4月至2014年3月住院的疑似艰难梭菌感染(CDI)患者1565份粪便样本进行Quik Chek检测,对GDH抗原阳性/毒素阴性样本追加产毒培养,按结果分三组分析CDI风险因素。结果显示PPI使用是CDI发展的显著风险因素,TC组与TP组具有相同的CDI高风险。

要点

  • 粪便直接Quik Chek检测阳性率为7.0%(109/1565例)。
  • GDH抗原阳性/毒素阴性样本的产毒培养阳性率为35.3%(72/204例)。
  • PPI使用是CDI发展的显著风险因素,TC组与TP组风险相同。

核心结论

  • PPI使用是CDI发展的显著风险因素。
  • TC组患者与TP组具有相同的CDI发展高风险,识别TC组很重要。
  • 抗菌药物如碳青霉烯类、头孢菌素类和氟喹诺酮类也是风险因素。

研究设计与样本

  • 研究纳入2012年4月至2014年3月住院的疑似CDI患者1565份粪便样本。
  • 使用Quik Chek试剂盒检测粪便样本,对GDH抗原阳性/毒素阴性样本追加产毒培养。
  • 按Quik Chek结果分为TP组(n=109)、TN组(n=111)和TC组(n=72)。

主要发现

  • 粪便直接Quik Chek检测阳性率为7.0%(109/1565例)。
  • GDH抗原阳性/毒素阴性样本的产毒培养阳性率为35.3%(72/204例)。
  • CDI毒素检测的真实阳性率估计为11.6%(181/1565例)。
  • TN、TP、TC三组在住院天数(>50天)、WBC计数(>10000 WBCs/μl)和PPI使用上差异显著(P<0.05)。

关键数值与推荐

  • 住院天数>50天的OR:TP组1.61(95%CI 0.94-2.74),TC组2.98(95%CI 1.59-5.58)。
  • WBC计数>10000 WBCs/μl的OR:TP组2.16(95%CI 1.24-3.75),TC组2.24(95%CI 1.21-4.14)。
  • PPI使用的OR:TP组9.03(95%CI 4.9-16.6),TC组9.15(95%CI 4.59-18.2)。

临床怎么用

  • 对GDH抗原阳性/毒素阴性的粪便样本应追加产毒培养以识别TC组患者。
  • TC组患者与TP组同样具有CDI高风险,需引起临床重视。
  • 评估CDI风险时应关注PPI使用、抗菌药物使用、住院天数及WBC计数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, the diagnostic method of choice for Clostridium difficile infection (CDI) is a rapid enzyme immunoassay in which glutamate dehydrogenase (GDH) antigen and C. difficile toxin can be detected (C. diff Quik Chek Complete; Alere Inc.) (Quik Chek). However, the clinical significance remains unclear in cases that demonstrate a positive result for GDH antigen and are negative for toxin. In this study, we used the Quik Chek test kit on fecal samples, with an additional toxin detection step using a toxigenic culture assay for the aforementioned cases. CDI risk factors were assessed among the 3 groups divided by the Quik Chek test results. The study involved 1,565 fecal samples from patients suspected to have CDI who were hospitalized during the period of April 2012 to March 2014. The 3 groups were defined as follows: both GDH antigen positive and toxin positive (by Quik Chek test) (toxin-positive [TP] group, n = 109), both GDH antigen and toxin negative (toxin-negative [TN] group, n = 111), and positive only for GDH antigen but toxin positive with subsequent toxigenic culture (toxigenic culture [TC] group, n = 72). The gender, age, number of hospitalization days, white blood cell (WBC) counts, serum albumin levels, body mass index (BMI), fecal consistency, and use of antibacterials and proton pump inhibiters (PPIs) were analyzed. The positive rate for the fecal direct Quik Chek test was 7.0% (109/1,565 cases). However, toxigenic culture assays using the Quik Chek test for only the GDH-antigen-positive/toxin-negative samples were 35.3% positive (72/204 cases). As a result, the true positive rate for C. difficile toxin detection was estimated to be 11.6% (181/1,565 cases). Moreover, significant differences (P < 0.05) in the number of hospitalization days (>50 days), WBC counts (>10,000 WBCs/μl), and use of PPIs comparing the TN, TP, and TC groups, were observed. The odds ratios (ORs) for the development of CDI were 1.61 (95% confidence interval [CI], 0.94 to 2.74) and 2.98 (95% CI, 1.59 to 5.58) for numbers of hospitalization days, 2.16 (95% CI, 1.24 to 3.75) and 2.24 (95% CI, 1.21 to 4.14) for WBC counts, and 9.03 (95% CI, 4.9 to 16.6) and 9.15 (95% CI, 4.59 to 18.2) for use of PPIs in the TP and TC groups, respectively. These findings demonstrated that the use of PPIs was a significant risk factor for CDI development. Moreover, antibacterials such as carbapenems, cephalosporins, and fluoroquinolones were demonstrated to be risk factors. In conclusion, identification of the TC group of patients is thought to be important, as this study demonstrates that this group bears the same high risk of developing CDI as the TP group.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Ohshima T, Osaki T, Yamamoto Y, et al. Evaluation of Risk Factors for Clostridium difficile Infection Based on Immunochromatography Testing and Toxigenic Culture Assay. J Clin Microbiol. 2018. PMID: 30232129. doi:10.1128/JCM.00555-18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。